BDF Gestion Sells 7,658 Shares of Edwards Lifesciences Corporation $EW

BDF Gestion cut its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 17.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,825 shares of the medical research company’s stock after selling 7,658 shares during the period. BDF Gestion’s holdings in Edwards Lifesciences were worth $2,864,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences in the second quarter worth approximately $28,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at $26,000. NewSquare Capital LLC lifted its position in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Rakuten Securities Inc. boosted its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in Edwards Lifesciences in the second quarter worth $40,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EW shares. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday, October 31st. Evercore ISI increased their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday. Finally, Citigroup reaffirmed a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.95.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. The trade was a 22.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,465 shares of company stock valued at $3,804,610 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.0%

EW stock opened at $85.66 on Friday. The firm has a market capitalization of $49.71 billion, a PE ratio of 36.92, a P/E/G ratio of 3.81 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The stock’s 50 day moving average is $82.53 and its 200-day moving average is $79.27.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.